Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a lower drug dose make stem cell transplants safer?

NCT ID NCT07719946

Recruiting now Disease control Sponsor: Tata Memorial Centre Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial investigates whether giving a reduced dose of the drug cyclophosphamide after a half-matched stem cell transplant can prevent graft-versus-host disease (GVHD) while causing fewer side effects. The standard dose often leads to infections and slow immune recovery. Researchers will give 20 adults with blood cancers half the usual dose and monitor how well it controls GVHD and how quickly their immune system bounces back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a lower dose of the drug cyclophosphamide (25 mg/kg/day) given on days 3 and 4 after transplant
What this could lead to
If successful, this could make half-matched stem cell transplants safer by reducing infections and helping the immune system recover faster.
What could go wrong
This is a small, single-arm trial with only 20 participants and no comparison group. The lower dose may turn out to be less effective at preventing graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANT HEMATOLOGICAL MALIGNANCIES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Advanced Centre for Treatment, Research and Education in Cancer

    NOT_YET_RECRUITING

    Navi Mumbai, Maharashtra, 410210, India

  • Advanced Centre for Treatment, Research and Education in Cancer

    RECRUITING

    Navi Mumbai, Maharashtra, 410210, India

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.